AR and posterior cortical atrophy: Today, there are innovative and effective treatment options for patients suffering from metastatic castration-resistant PCa, for example androgen receptor antagonists (e.g., abiraterone or enzalutamide, cytotoxic (taxane-based) chemotherapies (e.g., with docetaxel or cabazitaxel), radiopharmaceuticals (e.g., high-energy delivering Radium-223) or novel immunotherapies (3, 4, 6, 7).